Aimmune Therapeutics (AIMT) PT Lowered to $52 at RBC Capital
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $52.00 (from $54.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
- Keysight Technologies (KEYS) PT Raised to $440 at UBS Amid Broad-Based AI Strength
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
